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LETTER  
Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy, accounting for 6% of non-Hodgkin lymphoma 
(NHL) and which remains incurable with standard therapy. Despite the approval of bortezomib
1
, temsirolimus
2
, 
lenalidomide
3
, ibrutinib
4
 and acalabrutinib
5
, patients with relapsed, refractory (R/R) MCL have a survival of 2 
years.  
 
Although ibrutinib monotherapy provides significant efficacy (overall response rate (ORR) 68% (complete 
response (CR) 21%; partial response (PR) 47%)) and tolerability in R/R MCL, patients ultimately relapse (median 
PFS 13.9 months) following Bruton’s tyrosine kinase inhibition (BTKi). 
 
There are minimal outcome data in patients progressing post-BTKi and the optimal approach is not 
established. Recent retrospective analyses have reviewed several agents (including traditional chemotherapy, 
lenalidomide, bortezomib, and Pi3Ki) in this setting. These collated data
6
 displayed an ORR 20-48% and a short 
progression-free survival (PFS) and overall survival (OS)
7,8
.  
 
Cheah and colleagues analyzed immunochemotherapy given post-ibrutinib (n=31). The ORR was 32% (CR 19%). 
The median OS was 8.4 months and median DOR was 6 months
7
. Martin and colleagues assessed therapy post-
ibrutinib (n=73). The ORR was 26% (CR 7%) resulting in a median PFS of 1.9 months and median OS 5.8 
months
9
. MCL-004 assessed a lenalidomide-based approach post-ibrutinib (PD 88%; toxicity 9%). The ORR to 
prior ibrutinib was 45%. Thirteen received lenalidomide, 11 lenalidomide-rituximab and 34 lenalidomide plus 
other therapy. The ORR was 29% and median DOR was 20 weeks.  
 
Outside of MCL-004, no specific regimen has assessed >15 BTKi-resistant patients. Existing therapies do not 
overcome unfavourable tumour biology in this setting and novel combinations with differing targeted 
mechanisms are required. 
 
BCL2 is overexpressed in MCL due to BCL2 loci amplification
10
, defective protein degradation via lack of E3 
ubiquitin ligase FBXO10, and transcriptional upregulation via BTK-mediated canonical NF-κB activation
11
.  
 
Venetoclax is a potent, selective, oral BCL2 inhibitor (BCL2i).  A recent phase 1 trial of venetoclax monotherapy 
(VEN-MONO) in NHL included 28 R/R MCL
12
. Within the whole cohort, toxicity was minimal and the ORR was 
75% in MCL (21% CR). The median PFS was 14 months with 800mg o.d. representing a safe dose sufficient to 
achieve durable remissions. Whilst these results are impressive, no patients had received prior BTKi. To our 
knowledge, there are no data outlining VEN-MONO efficacy outside of this initial publication and no data 
published post-BTKi. We retrospectively collected data on 20 R/R MCL patients treated with off-label, free-of-
charge VEN-MONO (03/2016-05/2018) via a UK-wide compassionate use programme supported by Abbvie. 
Data were collected from hospital records by the treating physician and included: response to prior lines 
including BTKi, duration on and reasons for stopping BTKi. Pre-venetoclax data collected included Ann Arbor 
stage, simplified prognostic index (sMIPI), histological subtype and Ki67% where available. Response was 
assessed by PET-CT or CT alone (Cheson 2014 criteria). 1 patient with heavy marrow infiltration at baseline was 
re-assessed with repeat marrow evaluation. 2 patients with marked lymphocytosis and splenomegaly were 
included in the ORR analysis as response was clearly assessable. 3 patients were evaluated clinically and 
therefore excluded from ORR analysis but included in the survival analysis. Induction immunochemotherapy 
included high-dose cytarabine (HDAraC) HDAraC/maxi-CHOP-R (cyclophosphamide, doxorubicin, vincristine, 
prednisolone, rituximab) and autologous stem-cell transplantation (ASCT) consolidation
13
. This pathway was 
considered a single treatment line. Rituximab maintenance following immunochemotherapy +/- ASCT was also 
included within first treatment. Following consent within a compassionate use programme, patients received 
VEN-MONO in a weekly ramp-up phase starting at 20-100mg o.d. to a maximum intended dose of 200-1200mg 
o.d. until progressive disease (PD), toxicity, death, physician or patient choice. Detailed dosing were available 
for 19/20 patients (Table S1). The final intended dose was 800mg o.d. for 7/19 (37%) patients and 1200mg o.d. 
for 9/19 (47%) patients. The final intended dose was reached in 14/19 (74%) patients. Intended dose was not 
obtained because of neutropenia (n=1), sepsis (n=1), and PD (n=3). 5 patients who reached final intended dose 
required a subsequent dose reduction (Table S1).  
 
Adverse event (AE) data, the incidence of tumour lysis syndrome (TLS), and anti-urate therapy were collected. 
AE grading were collected according to CTCAEv4.03. Follow-up was censored at the most recent hospital visit 
or death. Non-responsive MCL was defined as stable disease (SD) or PD. Data were censored in 05/2018. PFS, 
OS and DOR were calculated in standard fashion. Statistical analyses were performed in XLSTAT. 
 
The median age was 69 (range 43-84) years with a typical male predominance (85%) (Table 1). Patients 
received a median of 3 prior therapies (range 2-5). 40% received a HDAraC-based induction regimen, with 30% 
receiving ASCT in first remission. At relapse (first or subsequent), all received a BTKi (ibrutinib (n=17), ibrutinib 
with donor lymphocyte infusion (n=1), tirabrutinib (n=2)). ORR to BTKi was 55% (CR 15%), with a median PFS of 
only (range 0.7-34.9) 4.8 months. Eighteen patients stopped BTKi due to PD and 2 for toxicity (grade (G)4 
thrombocytopenia; G4 subdural haemorrhage). Post-BTKi, four relapsed with blastoid MCL (Table 2). Prior to 
VEN-MONO, 95% had stage III/IV disease. 50% (9/18) were high-risk according to s-MIPI.  Median Ki67% was 
45% (11 biopsies assessed).  
 
VEN-MONO was well tolerated. There was no clinical TLS and 4 transient, asymptomatic biochemical TLS; 
managed with successful temporary cessation and re-challenge (Table S2). Three patients required dose 
reductions to 600mg o.d. due to AEs (G2 fatigue (n=1), G2 diarrhoea (n=2)).  There were 17 AEs reported 
including pneumonia (G3; n=3), sepsis (G4; n=1), fatigue (G2; n=2), neutropenia (G2; n=2) and diarrhoea (G2; 
n=3) (Table S3). Patients received allopurinol (45%), rasburicase (30%) or both (25%) as prophylaxis (Table 2).   
 
The ORR to VEN-MONO was 53% (18% CR; 35% PR). The median time to response on venetoclax was 48 
(range: 14-204) days. The median PFS was 3.2 months (95% CI 1.2-11.3 months) and the median OS was 9.4 
months (95% CI 1.5 months-not reached (NR)) (Figure 1A-B). The median DOR was 8.1 (95% CI 2.8-9.8) months 
and the PFS was significantly improved in venetoclax responders (median 10.7 months (95% CI 3.7-12.3)) 
versus non-responders (median 1.1 months (95% CI 0.8-2.6); p=0.002) (Figure 1C; Supplementary Figure 1A). 
Although the initial ORR to venetoclax varied according to prior BTKi response (primary resistance to BTKi 
(n=8): ORR 38% versus response to BTKi (n=9): ORR 67%) (p=0.24)), this did not translate to an improved PFS 
(data not shown). Duration on ibrutinib (<4 vs. >4 months) did also not predict for PFS to VEN-MONO (p=0.13) 
(Figure 1D).  The s-MIPI pre-venetoclax also did not predict PFS (p=0.714) (Supplementary Figure 1B). The PFS 
for the 2 patients that stopped ibrutinib due to toxicity were 4.3 months (best response: SD) and 10.0 months 
(best response: PR) respectively. 
 
Patients who received only 2 prior lines pre-VEN-MONO had a paradoxically shorter PFS (median 1.3 months 
(95% CI 0.8-2.6)) compared to more heavily pre-treated (>2 prior lines) (median 10.0 months (95% CI 3.7-NR); 
p=0.042). Similar results were seen when comparing patients with a time from initial MCL diagnosis to start of 
venetoclax of >4.5 years (median 10.0 months (95% CI 2.6-NR)) versus <4.5 years (median 1.3 months (95% CI 
0.8-4.3); p=0.027) (Supplementary Figure 1C-D). As such, less heavily pre-treated patients were enriched for 
those with a considerably shorter time from MCL diagnosis to venetoclax commencement and therefore likely 
represented those with more aggressive disease biology. 4 patients with blastoid disease had a short time 
from diagnosis to VEN-MONO (0.8-2.1 years), possessed high Ki67% (75-90%), had a ORR of 25%, and all 
progressed by 2 months. Eight patients received treatment post-VEN-MONO (Table S4). One patient received 
an alloSCT following response to VEN-MONO but subsequently relapsed.  
 
To date, 12 patients have died; 9 from PD, 2 from the combination of PD and infection, and 1 patient from 
secondary acute myeloid leukaemia whilst in remission post R-BAC (Table S5). 
 
We present initial real-world data outlining the efficacy of VEN-MONO in a patient cohort with aggressive MCL 
who had failed BTKi. The ORR and median PFS to BTKi is markedly inferior to the pivotal trials with ibrutinib
4
 
and acalabrutinib
5
, suggesting our cohort possessed particularly adverse clinical and biological features. We 
provide the first evidence of VEN-MONO tolerability and efficacy in MCL the post-BTKi setting. An ORR 53% (CR 
18%) is encouraging and compares favorably with other treatments in this setting; however the median PFS 
was short. VEN-MONO responses in BTKi resistance provides extension of the proof-of-principle initially 
obtained in chronic lymphocytic leukemia that BH3 mimetics have activity in BTKi-resistant 
lymphoproliferative disease
14
. Subgroup analysis was limited by small numbers but prior BTKi response or 
duration did not predict PFS.  
 
Weaknesses in our study include the intrinsic biases associated with retrospective data reporting, the lack of 
centralized pathology review, formalized radiological reporting, and prospective AE reporting.  
 
VEN-MONO provides an encouraging initial ORR in R/R MCL post-BTKi with minimal toxicity and therefore 
provides further evidence for its place investigating rational novel combinations in this setting.  Specific clinical 
benefit was gained in responding patients but the overall PFS was disappointing. Synergy between BTKi and 
BCL2i has been demonstrated in BTK-sensitive and resistant MCL cells in-vitro and in-vivo
11
 and early clinical 
data combining ibrutinib-venetoclax (n=24) suggest safety, high complete metabolic responses (71%) and high 
MRD-negativity (67% marrow; 8-colour flow cytometry)
15
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 Table 1: Baseline characteristics: prior therapies 
All patients (N=20) n (%) 
Gender   
Male 17 (85%) 
Female 3 (15%) 
First line therapy   
CHOP+/-R or CHOP-like 6 
Fludarabine-based+/-R 4
a
 
MAXI-CHOP/HDAC+/-R 8 
Other 2
b
 
a)      Included FMC RIC alloSCT in CR1 
  
b)      R-VCAP, R-chlorambucil 
  
ASCT Consolidation in 1
st
 remission   
Yes 6 (30%) 
No 14 (70%) 
Rituximab Maintenance in 1
st
 remission   
Post immunochemotherapy 2 (10%) 
Post ASCT 0 (0%) 
Neither 18 (90%) 
Duration of exposure to BTK inhibitor (months; range) 4.77 months 
(range 0.66 – 34.85 months) 
Response rate to prior BTK inhibitor ORR 11/20 (55%) 
CR 3 (15%) 
PR 8 (40%) 
SD 4 (20%) 
PD 5 (25%) 
Reason for BTK inhibitor discontinuation (n = 20)   
Progressive disease 17 
Stable disease 1 
Toxicity 2 
 
Abbreviations: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone), R (rituximab), HDAC (high 
dose cytarabine), RIC (reduced intensity conditioning), FMC (fludarabine, melphalan, alemtuzumab (campath)), 
AlloSCT (allogenic stem cell transplantation), VCAP (bortezomib (velcade), cyclophosphamide, doxorubicin, 
prednisolone), ASCT (autologous stem cell transplantation), BTK (bruton tyrosine kinase)  
  
 Table 2: Baseline characteristics: pre-VEN-MONO 
   
Age prior to Venetoclax use Median 69 (43-84) years 
Prior lines of therapy pre-Venetoclax Median 3 prior lines (range 2-5) 
  
Stage 1-2 1 
Stage 3-4 19 
    
Extranodal disease Y / N
 
a) bone marrow n = 12; liver n = 1; skin n = 2; pleural/pulmonary n = 2  
Y 17 / N 3
a 
   
LDH > ULN 15 
    
ECOG PS 0-1 11 
ECOG PS 2-4 9 
sMIPI 0-3  4 
sMIPI 4-6 5 
sMIPI 7-9
 
  11
 
Ki67%
 
b) 11 biopsies assessed for Ki67% pre-venetoclax
 
Median 45% (range 10-90%)
b 
   
Histology Small cell 7 
  Classical 3 
  Pleomorphic 3 
 
Blastoid 4 
 
Not known 3 
Anti-Urate Agent used   
Allopurinol 9 (45%) 
Rasburicase 6 (30%) 
Both 5 (25%) 
Neither 0 (0%) 
Abbreviations: LDH (lactate dehydrogenase), ECOG PS (eastern cooperative oncology group performance 
status), R (rituximab), BAC (bendamustine, cytarabine), SCT (stem cell transplantation), AML (acute myeloid 
leukaemia).  
 
  
Figure Legend 
Overall Title: Survival outcome of patients with relapsed, refractory MCL on venetoclax monotherapy 
Figure 1A – Progression free survival of all patients 
Figure 1B – Overall survival of all patients 
Figure 1C – Duration of response 
Figure 1D – Progression free survival according to duration on ibrutinib 

Table	S1:	Dose	ramp	up	schedule	on	VEN-MONO	(n	=	19)	
Final	dose	
intention	
Ramp	up	schedule	 Highest	dose	reached	
200	mg	OD	 weekly	ramp	up	20mg,	50mg,	100mg	 100	mg	OD	(stopped	early:	sepsis)	
400	mg	OD	 weekly	ramp	up:	20mg,	50mg,	100mg,	200mg,	400mg	 400	mg	OD	
400	mg	OD	 weekly	ramp	up:	20mg,	50mg,	100mg,	200mg,	400mg	 400	mg	OD	
800	mg	OD	 weekly	ramp	up:	20mg,	50mg,	100mg,	200mg,	400mg,	800mg	 800	mg	OD	
800	mg	OD	 weekly	ramp	up	20mg,	50mg,	100mg,	200mg,	400mg,	800mg	 800	mg	OD	
800	mg	OD	 weekly	ramp	up:	50mg,	100mg,	200mg,	400mg,	800mg	 800	mg	OD	
800	mg	OD	 weekly	ramp	up:	50mg,	100mg	3	days,	200mg	10	days,	400mg	 400	mg	OD	(stopped	early:	PD)	
800	mg	OD	 weekly	ramp	up:	20mg,	50mg,	100mg,	200mg,	400mg,	600mg,	800mg	 800	mg	OD	
800	mg	OD	 weekly	ramp	up:	20mg,	50mg,	100mg,	200mg,	400mg	 400	mg	OD	but	reduced	to	200	mg	OD	due	to	G2	neutropenia	
800	mg	OD	 weekly	ramp	up:	starting	at	100mg,	200mg,	400mg,	800mg		 800	mg	OD	
1200	mg	OD	 weekly	ramp	up:	20mg,	50mg,	100mg,	200mg,	400mg,	800mg,	1200mg	 1200	mg	OD	but	reduced	to	600	mg	OD	due	to	G2	fatigue	and	G3	
LRTI	
1200	mg	OD	 weekly	ramp	up:	20mg,	50mg,	100mg,	200mg,	400mg,	800mg,	1200mg	 1200	mg	OD	but	reduced	to	800	mg	OD	due	to	G2	diarrhoea	and	
G2	nausea	
1200	mg	OD	 weekly	ramp	up:	20mg,	50mg,	100mg,	200mg,	400mg,	800mg,	1200mg	 1200	mg	OD	but	reduced	to	800mg	OD	due	to	G2	diarrhoea	
1200	mg	OD	 weekly	ramp	up:	20mg,	50mg,	100mg,	200mg	 200	mg	OD	(stopped	early:	PD)	
1200	mg	OD	 weekly	ramp	up	20mg,	50mg,	100mg,	200mg,	400mg,	800mg,	1200mg	 1200	mg	OD	
1200	mg	OD	 weekly	ramp	up:	20mg,	50mg	 50	mg	OD	(stopped	early:	PD)	
1200	mg	OD	 weekly	ramp	up:	50mg,	100mg,	200mg,	400mg,	800mg,	1200mg	 1200	mg	OD	
1200	mg	OD	 weekly	ramp	up:	50mg	4	days,	100mg	3	days,	200mg	3	days,	400mg	3	days,	
800mg	2	days,	1200mg	3	days	
1200	mg	OD	
1200	mg	OD	 weekly	ramp	up:	20mg,	50mg,	200mg,	400mg,	800mg,	1200mg	 1200	mg	OD	but	reduced	to	600	mg	OD	due	to	G2	diarrhoea	
	
	
	
	
	
	
	 Starting	
dose	
(mg)	
Episodes	of	
biochemical	
TLS	meeting	
Howard	
Criteria	
Dosing	ramp	up	 Dose	at	
which	
Howard	
criteria	
occurred	
Anti-urate	 Outcome	 Worst	biochemical	abnormalities	
(ranges	given	where	available)	
Patient	
1	
100	mg	
OD	
2	 100mg;	stopped	after	
single	dose.	Held	for	5	
days	and	restarted	at	
100mg	then	weekly	
escalation	(200mg;	
400mg;	800mg).	
Recurrent	TLS	at	800mg.	
100	mg	
800	mg	
Rasburicase	and	
IV	fluids	on	both	
occasions	
1) Dose	held	for	5	days	then	
rechallenged	and	successfully	
escalated		
2) Dose	held	for	24	hours	then	
rechallenged	at	400mg	and	
successfully	escalated		
1) PO4	3.01	(0.65-1.05),	Adj	Ca	1.95,	K+	5.9,	Urate	
<0.03	(had	receive	rasburicase)	
2) PO4	2.43	(0.65-1.05),	Urate	0.68	(0.21-0.42),	Adj	
Ca	2.11	(2.10-2.60),	K+	4.0	(3.5-5)	
Patient	
2	
50	mg	
OD	
1	 Weekly	ramp	up:	50mg,	
100mg;	200mg;	400mg.	
Final	dose	400mg.		
50	mg	 rasburicase	and	
IV	fluids;	
haemodialysis	
Dose	ramp	up	in	weekly	fashion.	
Haemodialysis	for	metabolic	
acidosis	at	full	dose	but	not	
clearly	due	to	TLS	at	that	time.	
Did	not	hold	venetoclax	dosing.		
PO4	1.84	
Adj	Ca	1.95	
K+	6.3	
Urate	0.36	(subsequently	<0.03	with	rasburicase)	
Patient	
3	
50	mg	
OD	
1	 50mg	for	1	day	then	
interrupted	for	2	days	
then	6	days	then	weekly	
ramp	up:	100mg;	200mg;	
400mg,	800mg;	1200mg.	
50	mg	 rasburicase	and	
IV	fluids	
Dose	held	for	2	days.	Resolved	
and	successfully	restarted	and	
dose	ramped	up.	
PO4	1.75	(0.8-1.5)	
Adj	Ca	2.06	(2.2-2.6)	
K+	5.2	(3.5-5.3)	
Urate	<30	and	subsequently	109	despite	rasburicase	
given	pre	(200	to	430)	
Patient	
4	
20mg	
OD	
1	 Weekly	ramp	up:	20mg;	
50mg,	100mg;	200mg;	
400mg;	800mg.			
Single	episode	after	9	day	
omission	(moderate	
neutropenia	and	line	
sepsis)	on	400mg	when	
restarted	at	same	dose.		
800	mg	 Rasburicase	and	
IV	fluids	
	
There	was	no	TLS	seen	at	all	in	
initial	ramp	up	phase.		The	single	
episode	of	lab	TLS	occurred	after	
a	9	day	Venetoclax	omission.	All	
settled	spontaneously	and	
reloaded	starting	at	20mg	with	no	
recurrent	TLS.	
PO4	3.1	(0.8-1.5)	
Adj	Ca	1.76	(2.2-2.6)	
K+	5.8	
Urate	559	(200-430)		
Table	S2:	Summary	data	for	Laboratory	TLS	events	(n	=	4)	
	
Table	S3:	Adverse	Events	on	VEN-MONO	
All	patients	(n=20)	 n	(%)	
Dose	reductions	from	target	dose	required	 5	(25%)	
Reasons:	Grade	2	fatigue	(n	=	1),	Grade	2	diarrhoea	(n	=	2),	Grade	2	
diarrhoea	alongside	grade	2	nausea	(n	=	1),	grade	2	neutropenia	(n	=	1)	
		
Grade	4	sepsis	 1	(5%)	
Grade	3	pneumonia	 3	(15%)	
Grade	2	diarrhoea	 3	(15%)	
Grade	2	fatigue	 2	(10%)	
Grade	2	headache	 2	(10%)	
Grade	2	neutropenia	 2	(10%)	
Grade	2	nausea	 2	(10%)	
Grade	2	raised	gamma	GT	 1	(5%)	
Grade	1	anaemia	 1	(5%)	
Biochemical	Tumour	lysis	 5	(25%)	
Clinical	Tumour	lysis	syndrome	 0	(0%)	
No	adverse	effects	reported	 12	(60%)	
	
Supplementary	Table	S4:	Treatment	post	VEN-MONO	
	 		
Allogenic	stem	cell	transplantation	 1	
R-BAC	
a)	1	patient	R-BAC	given	with	aim	to	bridge	to	allogenic	SCT;	developed	
secondary	AML	in	remission	
2a	
R-Bendamustine	 2	
Lenalidomide-based+/-R	 2	
Ibrutinib	 2	
Nil	 12	
 
ASCT	in	CR1	
R-M
	
Line	BTK	given	
Tim
e	on	IBR	
(m
onths)	
Reason	for	
Cessation	of	
IBR	
O
RR	to	BTKi	
Prior	lines	
Diagnosis	to	
VEN
	(years)	
Stage	
Age	at	VEN
	
Extranodal	
LDH	raised	
W
CC	
ECO
G
	PS	
s-M
IPI	
Histology	
Ki67%
	
Cycles	
Biochem
	TLS	
Best	O
RR	to	
VEN
	
Toxicity	
Treatm
ent	
post	VEN
	
Dose	
reduction	
(M
G
)	
Follow
	up	
(m
onths)	
*=	progression	
Y	 N	 3	 30.1	 PD	 CR	 4	 10.1	 4	 69	 periorbital	
mass	
N	 4.2	 2	 3	 NK	 N/A	 2	 N	 N/A	 Nil	 Nil	 Nil	 2.0*	
N	 N	 3	 3.1	 PD	 PD	 3	 11.0	 3	 56	 Nil	 N	 10.0	 0	 3	 small	cell	 30%	 9	 N	 N/A	 G2	fatigue.	G3	
Pneumonia	x	2.	
Nil	 600	 9.1	
Y	 N	 2	 2.2	 PD	 PD	 2	 2.1	 4	 56	 BM	 Y	 3.2	 1	 3	 blastoid	 90%	 1.5	 Y	 PD	 G2	diarrhoea	
G2	Nausea	
LEN-Dex	1	
cycle	
Nil	 1.5*	
N	 N	 3	 34.5	 PD	 PR	 3	 5.6	 4	 80	 BM	 N	 4.8	 1	 3	 classical	 40%	 12	 N	 PR	 G2	diarrhoea	 IBR	->	BR	
ongoing	
600	 12.3*	
N	 N	 2	 3.1	 Toxicity	
(grade	
4	low	
PLTs)	
PD	 4	 1.4	 4	 43	 Liver,	BM	 Y	 7.6	 2	 4	 classical	 10%	 5	 N	 SD	 Nil	 R-BAC	then	
developed	
secondary	
AML	
Nil	 4.3*	
N	 N	 5	 5.6	 PD	 PR	 5	 9.0	 4	 57	 BM	 N	 10.1	 0	 4	 classical	 N/A	 6	 N	 PR	 Nil	 Nil	 Nil	 6.0	
Y	 N	 2	 10.8	 PD	 CR	 4	 8.6	 4	 67	 Lung	 Y	 5.7	 0	 5	 small	cell	 80%	 0.5	 N	 PD	 Nil	 Nil	 Nil	 0.8*	
N	 N	 2	 3.2	 PD	 PD	 2	 0.8	 4	 70	 BM	 Y	 1.8	 3	 5	 blastoid	 80%	 1.5	 Y	 PD	 Nil	 R-BAC	x	1	
cycle	
Nil	 0.8*	
N	 Y	 4	 0.7	 Toxicity	
(grade	
4	SDH)	
SD	 4	 4.7	 3	 69	 Nil	 Y		 NK	 3	 6+	 pleomorphic	 N/A	 10.
5	
N	 PR	 Nil	 IBR	 Nil	 10.0*	
N	 N	 5	 31.7	 PD	 PR	 5	 8.3	 4	 66	 Breast	 Y	 10.5	 1	 6	 small	cell	 N/A	 6.5	 N	 CRu	 G2	Headache;	G2	
Nausea;	G2	
Neutropenia;	G1	
Anaemia;	G1	low	
PLTs;	G2	raised	
GGT	
Nil	 Nil	 6.4	
N	 N	 3	 32.2	 PD	 PR	 3	 5.2	 4	 70	 BM	 N	 26.2	 3	 7	 pleomorphic	 N/A	 10	 N	 PR	 Nil	 Nil	 Nil	 10.2	
N	 N	 2	 34.8	 PD	 PR	 2	 4.6	 4	 79	 BM	 Y	 8.1	 0	 7	 NK	 45%	 3.5	 N	 PD	 Nil	 LEN-R	ongoing	 Nil	 2.6*	
Y	 N	 2	 3.7	 PD	 PR	 2	 1.6	 4	 57	 BM	 Y	 145.
0	
3	 8	 small	cell	 N/A	 1	 N	 PR	 G4	Sepsis	 Nil	 Nil	 1.1*	
Y	 N	 2	 1.1	 PD	 SD	 2	 2.8	 4	 56	 BM	 Y	 193.
9	
1	 7	 pleomorphic	 N/A	 1	 Y	 PD	 Nil	 Nil	 Nil	 0.8*	
N	 N	 3	 26.7	 PD	 PR	 3	 4.5	 4	 77	 Lung,	
Pleura	
Y	 4.1	 3	 7	 NK	 N/A	 1	 N	 PD	 Nil	 Nil	 Nil	 0.5*	
 
Table	S5:	Summary	data	for	all	patients	
 
 
Y	 N	 2	 4.0	 PD	 SD	 2	 1.3	 4	 60	 BM	 Y	 269	 2	 8	 small	cell	 45%	 9	 Y	 CR	 Nil	 Allograft	->	
relapse	->	
PEP-C	ongoing	
Nil	 11.3*	
N	 Y	 2	 1.3	 PD	 PD	 2	 0.9	 1	 73	 Nil	 Y	 10.5	 1	 8	 blastoid	 80%	 2	 N	 PD	 Nil		 BR	 Nil	 2.2*	
N	 N	 2	 2.0	 SD	 SD	 2	 1.3	 4	 79	 Skin	 Y	 18.4	 1	 9	 Blastoid	 75%	 1.2
5	
N	 Cru	 G2	fatigue.	
G2	Neutropenia	
Nil	 Nil	 1.2*	
N	 N	 3	 29.3	 PD	 CR	 3	 5.9	 4	 84	 BM	 Y	 65.5	 1	 9	 Small	cell	 N/A	 13	 N	 PR	 G2	diarrhoea	 Nil	 600	 13.1	
N	 N	 5	 19.0	 PD	 PR	 5	 8.2	 4	 72	 BM	 Y	 19.6	 2	 10	 small	cell	 15%	 4	 Y	 PR	 Nil	 Nil	 Nil	 3.7*	
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